| GPR108 is a highly conserved AAV entry factor AM Dudek, N Zabaleta, E Zinn, S Pillay, J Zengel, C Porter, ... Molecular Therapy 28 (2), 367-381, 2020 | 96 | 2020 |
| Novel vectors and approaches for gene therapy in liver diseases S Maestro, ND Weber, N Zabaleta, R Aldabe, G Gonzalez-Aseguinolaza JHEP Reports 3 (4), 100300, 2021 | 84 | 2021 |
| Successful repeated hepatic gene delivery in mice and non-human primates achieved by sequential administration of AAV5ch and AAV1 A Majowicz, D Salas, N Zabaleta, E Rodríguez-Garcia, ... Molecular Therapy 25 (8), 1831-1842, 2017 | 82 | 2017 |
| CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I N Zabaleta, M Barberia, C Martin-Higueras, N Zapata-Linares, I Betancor, ... Nature communications 9 (1), 5454, 2018 | 68 | 2018 |
| Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice D Reichart, GA Newby, H Wakimoto, M Lun, JM Gorham, JJ Curran, ... Nature medicine 29 (2), 412-421, 2023 | 59 | 2023 |
| An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates N Zabaleta, W Dai, U Bhatt, C Hérate, P Maisonnasse, JA Chichester, ... Cell host & microbe 29 (9), 1437-1453. e8, 2021 | 55 | 2021 |
| Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates D Salas, KL Kwikkers, N Zabaleta, A Bazo, H Petry, SJ van Deventer, ... Blood advances 3 (17), 2632-2641, 2019 | 46 | 2019 |
| Genetic-based approaches to inherited metabolic liver diseases N Zabaleta, M Hommel, D Salas, G Gonzalez-Aseguinolaza Human Gene Therapy 30 (10), 1190-1203, 2019 | 29 | 2019 |
| Gene therapy for liver diseases—Progress and challenges N Zabaleta, C Unzu, ND Weber, G Gonzalez-Aseguinolaza Nature Reviews Gastroenterology & Hepatology 20 (5), 288-305, 2023 | 21 | 2023 |
| mRNA and gene editing: Late breaking therapies in liver diseases N Zabaleta, L Torella, ND Weber, G Gonzalez‐Aseguinolaza Hepatology 76 (3), 869-887, 2022 | 17 | 2022 |
| Ancestral library identifies conserved reprogrammable liver motif on AAV capsid E Zinn, C Unzu, PF Schmit, HT Turunen, N Zabaleta, J Sanmiguel, ... Cell Reports Medicine 3 (11), 2022 | 12 | 2022 |
| Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mouse and non-human primates N Zabaleta, W Dai, U Bhatt, JA Chichester, J Sanmiguel, R Estelien, ... bioRxiv, 2021.01. 05.422952, 2021 | 11 | 2021 |
| Improvement of Adeno-Associated Virus-Mediated Liver Transduction Efficacy by Regional Administration in Macaca fascicularis N Zabaleta, D Salas, M Paramo, M Hommel, V Sier-Ferreira, ... Human Gene Therapy Clinical Development 28 (2), 68-73, 2017 | 9 | 2017 |
| Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep. 3, 100300 S Maestro, ND Weber, N Zabaleta, R Aldabe, G Gonzalez-Aseguinolaza | 8 | 2021 |
| In vitro and in vivo genetic disease modeling via NHEJ-precise deletions using CRISPR-Cas9 S López-Manzaneda, I Ojeda-Pérez, N Zabaleta, A García-Torralba, ... Molecular Therapy-Methods & Clinical Development 19, 426-437, 2020 | 8 | 2020 |
| Inhibition of MicroRNA 6937 delays photoreceptor and vision loss in a mouse model of retinitis pigmentosa A Anasagasti, A Lara-López, S Milla-Navarro, L Escudero-Arrarás, ... Pharmaceutics 12 (10), 913, 2020 | 6 | 2020 |
| AdrA as a potential immunomodulatory candidate for STING-mediated antiviral therapy that required both type I IFN and TNF-α production E Rodriguez-Garcia, N Zabaleta, I Gil-Farina, M Gonzalez-Aparicio, ... The Journal of Immunology 206 (2), 376-385, 2021 | 5 | 2021 |
| CRISPR/Cas9-mediated disruption of glycolate oxidase is an efficacious and safe treatment for primary hyperoxaluria type I N Zabaleta, M Barberia, C Martin-Higueras, N Zapata, I Betancor, ... MOLECULAR THERAPY 26 (5), 384-385, 2018 | 5 | 2018 |
| Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques N Zabaleta, U Bhatt, C Hérate, P Maisonnasse, J Sanmiguel, C Diop, ... Molecular Therapy 30 (9), 2952-2967, 2022 | 4 | 2022 |
| Computed tomography and [18F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates T Naninck, N Kahlaoui, J Lemaitre, P Maisonnasse, A De Mori, Q Pascal, ... Iscience 25 (4), 2022 | 4 | 2022 |
